Clinical Trials Directory
We are doing this study to find out if pelvic floor physical therapy can improve sexual function for women who have undergone pelvic radiation.
We are doing this study to see if the study drug, dostarlimab, can reduce the recurrence of cancer in people who have had their colon cancer surgically removed.
We are doing this study to understand whether people who receive a lower radiation dose after an interim (the second scan) PET-CT identifies an early treatment response have a similar outcome to those receiving a standard radiation dose.
The results of the interim PET-CT scan will be used to guide your radiation dose plan. Depending on the PET-CT results, you will either receive a reduced radiation dose or the standard radiation dose for your cancer.
We are doing this study to find out if an experimental drug called navtemadlin (the study drug) is a safe and effective option for people with myelofibrosis (MF). We want to know how well it works when it is combined with ruxolitinib for people who did not get the desired results from ruxolitinib on its own.
We are doing this study to see if taking a prebiotic (dietary supplement) can reduce the risk of acute graft-versus-host disease (a common complication) in people who receive an allogeneic stem cell transplant. This study is important because prebiotics are a common and safe dietary supplement, and there is a need for a safe and effective way to reduce graft-versus-host disease after transplant.
We are doing this study to find out if an experimental drug called INBRX-109 (the study drug) is a safe and effective option for people with unresectable or metastatic conventional chondrosarcoma.
We are doing this study to find the most effective, safe dose of an experimental drug called CLN-049 (the study drug) for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
We are doing this study to find the most effective, safe dose of an experimental drug called V940 (the study drug) when it is given with pembrolizumab to people who have had surgery to remove their bladder, kidney, or other organs for muscle-invasive urothelial carcinoma. We want to know how well this combination works compared to taking pembrolizumab on its own.